
Bruker Corporation
BRKRNASDAQHealthcareMedical - Devices
Previous close
$59.56
−$0.36 · -0.60%
BRKR company overview
Regular session · ET · Market data may be delayed.
GoAI snapshot
AI-powered factor overview
GoAI score
Sell
Trim exposure — unfavorable risk-reward
Valuation
18
Overpriced
Momentum
61
Gaining
Sentiment
60
Mixed
Risk resilience
56
Elevated Risk
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
AI-generated, informational only, and not investment advice.
Company profile
Company websiteBruker Corporation stands as a prominent global developer, manufacturer, and distributor of cutting-edge scientific instruments, alongside comprehensive analytical and diagnostic solutions. Its operations are structured across three distinct segments: Bruker Scientific Instruments (BSI) Life Science, BSI NANO, and Bruker Energy & Supercon Technologies. The company's extensive portfolio for life sciences encompasses a variety of advanced tools, including single and multi-modality systems, sophisticated mass spectrometry platforms, and critical diagnostic solutions. These diagnostics feature the acclaimed MALDI Biotyper for swift pathogen identification, various molecular diagnostic kits (such as genotype and fluorotype offerings), DNA test strips, and fluorescence-based polymerase chain reaction (PCR) technology, notably including SARS-CoV-2 testing solutions for COVID-19 diagnosis and Fluorotyper-SARS-CoV-2 plus kits. Beyond life science, Bruker delivers a wide array of specialized instruments for research, analysis, and process control. This includes portable analytical and bioanalytical detection systems, a full range of X-ray instruments (from analytical tools for electron microscopes to handheld, portable, and mobile X-ray fluorescence spectrometry devices), and sophisticated atomic force microscopy (AFM) instrumentation for non-contact nanometer resolution topography. Furthermore, it supplies automated X-ray metrology, automated AFM defect-detection, and equipment for photomask repair and cleaning. The company also excels in advanced optical fluorescence microscopy and provides critical products and services supporting multi-omics research for drug and biomarker discovery. Within its energy sector, Bruker is a key provider of superconducting materials, particularly metallic low-temperature superconductors, and develops complex tools and devices utilizing these materials, alongside other high-technology tools like synchrotron and beamline instrumentation. Reflecting its commitment to innovation, Bruker Corporation collaborates with Newomics Inc. on an LC-MS platform specifically tailored for drug discovery applications. Established in 1991, the corporation maintains its headquarters in Billerica, Massachusetts.
- Industry
- Medical - Devices
- Sector
- Healthcare
- Headquarters
- US
- CEO
- Frank H. Laukien
- Listed since
- Aug 4, 2000
- Employees
- 11,085
Market position
Day range
Current $59.56
52-week range
Current $59.56
- Open
- $59.60
- Previous close
- $59.92
- Volume
- 3.2M
- 1.31× average
- Average volume
- 2.44M
- Average daily volume
- Market cap
- 9.07B USD
- Beta
- 1.28
- Market reference 1
- 50-day average
- $58.4742
- +1.86% above average
- 200-day average
- $47.1838
- +26.23% above average
Financials
Financial snapshot
Latest / TTMValuation & yield
- P/E (TTM)
- -85.21×
- P/B (TTM)
- 3.78×
- P/S (TTM)
- 2.59×
- Dividend yield
- 0.34%
Profitability & efficiency
- Gross margin
- 46.69%
- Operating margin
- 3.61%
- Net margin
- -2.03%
Financial health
- Debt / equity
- 0.8×
Financial statements
Margin trends
Profitability as a percentage of reported revenue.
Income trends
Revenue
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 3.44B USD | 3.37B USD | 2.96B USD | 2.53B USD | 2.42B USD |
| Cost of goods sold | 1.86B USD | 1.72B USD | 1.45B USD | 1.23B USD | 1.21B USD |
| Gross profit | 1.58B USD | 1.65B USD | 1.51B USD | 1.31B USD | 1.21B USD |
| Research and development | 395.2M USD | 376.5M USD | 294.8M USD | 235.9M USD | 220.8M USD |
| Selling, general, and administrative | 946.5M USD | 893.8M USD | 729.4M USD | 607.4M USD | 562.3M USD |
| Operating expenses | 1.34B USD | 1.4B USD | 1.08B USD | 873M USD | 796.3M USD |
| Interest income | 14.8M USD | 9.3M USD | 7.5M USD | 2.8M USD | 900K USD |
| Interest expense | 60.3M USD | 47.9M USD | 16.4M USD | 16.1M USD | 14.3M USD |
| Depreciation and amortization | 220.3M USD | 183.8M USD | 114.9M USD | 88.7M USD | 89.2M USD |
| Operating income | 236M USD | 253.1M USD | 436.9M USD | 432.7M USD | 413.3M USD |
| Net income | −8.6M USD | 113.1M USD | 427.2M USD | 296.6M USD | 277.1M USD |
Company facts updated Aug 24, 2026.
BRKR peers
ETFs holding BRKR
Funds reporting this stock among their holdings, ordered by reported position size.
iShares Core S&P Mid-Cap ETFIJH221.67M0.17%125.92B USD0.05%$76.77+0.52%
Vanguard Morningstar Total Stock Market ETFVTI213.12M0.01%2.3T USD0.03%$378.24+0.44%
Vanguard Morningstar Small-Cap ETFVB153.94M0.08%183.4B USD0.03%$304.76+0.64%
Vanguard Morningstar Small-Cap Value ETFVBR97.77M0.14%68.3B USD0.05%$249.18+0.68%
First Trust NYSE Arca Biotechnology Index FundFBT89.91M3.09%2.94B USD0.55%$271.07+1.10%
Vanguard Extended Market ETFVXF80.39M0.08%93.7B USD0.05%$245.53+0.82%
iShares Biotechnology ETFIBB49.77M0.47%10.75B USD0.44%$213.56+1.29%
State Street SPDR S&P MIDCAP 400 ETF TrustMDY48.76M0.18%26.72B USD0.23%$699.6+0.48%
iShares Core S&P Mid-Cap ETFIJH- Market value
- 221.67M
- Weight
- 0.17%
- AUM
- 125.92B USD
- Expense ratio
- 0.05%
- Price / 1D
- $76.77+0.52%
Vanguard Morningstar Total Stock Market ETFVTI- Market value
- 213.12M
- Weight
- 0.01%
- AUM
- 2.3T USD
- Expense ratio
- 0.03%
- Price / 1D
- $378.24+0.44%
Vanguard Morningstar Small-Cap ETFVB- Market value
- 153.94M
- Weight
- 0.08%
- AUM
- 183.4B USD
- Expense ratio
- 0.03%
- Price / 1D
- $304.76+0.64%
Vanguard Morningstar Small-Cap Value ETFVBR- Market value
- 97.77M
- Weight
- 0.14%
- AUM
- 68.3B USD
- Expense ratio
- 0.05%
- Price / 1D
- $249.18+0.68%
First Trust NYSE Arca Biotechnology Index FundFBT- Market value
- 89.91M
- Weight
- 3.09%
- AUM
- 2.94B USD
- Expense ratio
- 0.55%
- Price / 1D
- $271.07+1.10%
Vanguard Extended Market ETFVXF- Market value
- 80.39M
- Weight
- 0.08%
- AUM
- 93.7B USD
- Expense ratio
- 0.05%
- Price / 1D
- $245.53+0.82%
iShares Biotechnology ETFIBB- Market value
- 49.77M
- Weight
- 0.47%
- AUM
- 10.75B USD
- Expense ratio
- 0.44%
- Price / 1D
- $213.56+1.29%
State Street SPDR S&P MIDCAP 400 ETF TrustMDY- Market value
- 48.76M
- Weight
- 0.18%
- AUM
- 26.72B USD
- Expense ratio
- 0.23%
- Price / 1D
- $699.6+0.48%
Continue in GoAI
Research BRKRresearch.disclaimer





